WANG Huiling,YUE Zhongsheng,QIAN Yating,et al.Analysis and enlightenment of drug-related administrative penalty cases in medical institutions from 2020 to 2022[J].ZHONGGUO YAOFANG,2023,34(21):2578-2582.
WANG Huiling,YUE Zhongsheng,QIAN Yating,et al.Analysis and enlightenment of drug-related administrative penalty cases in medical institutions from 2020 to 2022[J].ZHONGGUO YAOFANG,2023,34(21):2578-2582. DOI: 10.6039/j.issn.1001-0408.2023.21.02.
Analysis and enlightenment of drug-related administrative penalty cases in medical institutions from 2020 to 2022
To analyze the patterns and characteristics of drug-related administrative penalty cases with medical institutions as parties from 2020 to 2022 in order to further improve drug management in medical institutions.
METHODS
2
A retrospective statistical analysis was used to summarize the drug-related administrative penalty decisions with medical institutions as parties, and to match them with the provisions of the
Drug Administration Law
(2019 version) for statistical analysis.
RESULTS
2
There were 144 complete administrative penalty decisions with medical institutions as parties. Analyzed by cause, 126 cases of administrative punishment for inferior drugs accounted for 87.50%, of which expired drugs accounted for more than 50.00% of the inferior drug cases; 15 cases (10.42%) were for purchasing drugs from enterprises or individuals not qualified to operate drugs. Analyzed by the range of punishment amount of the cases, 34 cases (23.61%) resulted in lighter penalties, while 81 cases (56.25%) resulted in reduced penalties.
CONCLUSIONS
2
There are extremely few medical institutions that have received administrative penalties for drug management violations. Medical institutions should strengthen the awareness of law-abiding, and know the red line of drug management and the illegal behavior that is easy to occur, so as to better strengthen drug quality management.
GOU J C . Amendments to the law to strengthen the regulation of pharmacies in medical institutions [N ] . China Pharmaceutical News , 2015-03-30 (003).
ZHANG L , ZHOU Q Y , HOU W J , et al . The responsibi- lity of using counterfeit and inferior drugs in the new Drug Administration Law from the perspective of medical institutions [J ] . Chin J Hosp Pharm , 2020 , 40 ( 15 ): 1679 - 1683 .
DENG G H , SONG Y . Construction of essential elements for the application of exemption clauses in drug admini- strative enforcement [J ] . China Food Drug Adm Mag , 2021 ( 10 ): 68 - 76 .
HU C Y . Research on perfecting the discretion system of administrative punishment in drug supervision:based on the analysis of the discretion system of relevant provincial drug supervision departments [J ] . Justice China , 2021 ( 9 ): 64 - 68 .
TAN Y . Circumstances of application of the reduction or exemption of penalties for illegal liability in the process of drug distribution and usage [J ] . Shanghai Med Pharm J , 2022 , 43 ( 9 ): 47 - 49,57 .
ZHANG X S . The application of “no fault and no punishment” in pharmaceutical trading enterprises and the significance of optimizing business environment [J ] . China Food Ind , 2022 ( 10 ): 52 - 54 .
Study on Main Changes of Counterfeit and Inferior Drugs ’Relevant Provisions in the Newly Revised Drug Administration Law and Their Impact on Law Enforcement